Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607810 · ClinicalTrials.gov registry record
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
A clinical trial of Diabetic Macular Edema and Diabetic Retinopathy, sponsored by Adverum Biotechnologies.
- Active
- Registry status
- 22
- Enrollment target
- 7
- Study locations
NCT05607810 is a study of Diabetic Macular Edema and Diabetic Retinopathy that is active but no longer recruiting, run by Adverum Biotechnologies. The registered enrollment target is 22 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT05607810, a study of Diabetic Macular Edema and Diabetic Retinopathy, is active but no longer recruiting, sponsored by Adverum Biotechnologies.
- ACTIVE NOT RECRUITING
- Registry status
- 22 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a prospective, observational study designed to evaluate the long-term safety and tolerability of ADVM-022 in participants with diabetic macular edema (DME). Participants who previously participated in the INFINITY parent study and received a single unilateral intravitreal dose of ADVM-022 are eligible for enrollment upon completion of the end of study visit in the parent study.
Conditions Studied
Interventions
- GENETIC ADVM-022
Study Locations (7)
Texas
- Adverum Clinical Site - Austin
- Adverum Clinical Site - Bellaire
- Adverum Clinical Site - The Woodlands
California
- Adverum Clinical Site - Beverly Hills
Nevada
- Adverum Clinical Site - Reno
Pennsylvania
- Adverum Clinical Site - Philadelphia
Other
- Adverum Clinical Site - Arecibo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-08-10 |
| Est. Completion | 2026-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05607810
The ClinicalTrials.gov registry entry for NCT05607810 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The listed sponsor is Adverum Biotechnologies, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which ADVM-022 is the first listed.
NCT05607810 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Texas, California, Nevada.
Frequently Asked Questions
What is clinical trial NCT05607810 about?
NCT05607810 is a clinical study titled "Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)". This is a prospective, observational study designed to evaluate the long-term safety and tolerability of ADVM-022 in participants with diabetic macular edema (DME). Participants who previously participated in the INFINITY parent study and received a single unilateral intravitreal dose of ADVM-022 ar...
What is the current status of trial NCT05607810?
This trial is currently active not recruiting. The enrollment target is 22 participants. The study started on 2022-08-10. Estimated completion is 2026-04.
What conditions does trial NCT05607810 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Diabetic Retinopathy.
What interventions are being tested in trial NCT05607810?
The interventions under investigation include: ADVM-022 (GENETIC).
Who is sponsoring clinical trial NCT05607810?
This trial is sponsored by Adverum Biotechnologies, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05607810 being conducted?
This trial has 7 study locations across California, Nevada, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
RECRUITING · Phase 3
-
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.